You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

53 search results for: mechanism of disease

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more
Type 2 Inflammation and Neuronal Sensitization in AD and PN
interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

Dermatology
Mechanisms of itch in normal skin and the effect of type 2 inflammation on neurons leading to chronic itch in atopic dermatitis and prurigo nodularis.
View more
The Impact <b>of</b> Skin Fibrosis in Patients with Prurigo Nodularis
videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

Dermatology
An animated infographic exploring the patient burden and pathophysiology of skin fibrosis in prurigo nodularis, specifically detailing how fibrotic pathways are driven and the key molecules involved.
View more
The Role <b>of</b> Chronic Inflammation in the Pathogenesis <b>of</b> CSU
expert video

The Role of Chronic Inflammation in the Pathogenesis of CSU

Dermatology
Drs. Kim and Saini discuss the role of chronic inflammation in the pathogenesis of CSU in this insightful interview.
View more
Diagnostic Considerations: Coexistence, and Distinctions <b>of</b> AD & PN
expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

Dermatology
Dr. Mark Tang talks about the coexistence of AD and PN and considerations for choosing treatment.
View more
Contributions <b>of</b> Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU
expert video

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

Dermatology
Dr. Elmariah introduces the multiple roles of type 2 cytokines in chronic itch.
View more
Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As
expert video

Skin Barrier, Neuroimmune Axis, and Type 2 Inflammation in Atopic Dermatitis - Q&As

Dermatology
Expert insights on the plasticity of inflammation, atopic dermatitis endotypes, and dysbiosis – Audience Q&A from the ADVENT symposium at ISID 2023.
View more
The Evolving Understanding <b>of</b> Prurigo Nodularis (PN) Has Implications for Patient Management
Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

Dermatology
An infographic summarizing the clinical manifestations and pathophysiological processes of PN.
View more
Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis
expert video

Key Type 2 Cytokines Impact the Skin Microbiome in Atopic Dermatitis

Dermatology
Dr. Stephan Weidinger explains how type 2 cytokines impact the skin microbiome in AD.
View more
The Impact <b>of</b> Skin Dysbiosis on Atopic Dermatitis
expert video

The Impact of Skin Dysbiosis on Atopic Dermatitis

Dermatology
Dr. Lisa Beck highlights key data from the ADRN Study demonstrating the correlation between skin dysbiosis, S. aureus colonization, and atopic dermatitis severity.
View more
Effect <b>of</b> Type 2 Inflammation on Skin Barrier Function in AD​
interactivity

Effect of Type 2 Inflammation on Skin Barrier Function in AD​

Dermatology
Gain insights on how type 2 inflammation affects different aspects of skin barrier function – an interactive educational tool.
View more
Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis
expert video

Evaluating the Responses to Biologic Therapies in Children With Atopic Dermatitis

Dermatology
Dr. Amy Paller shares her opinion on practical considerations for evaluating response during treatment with biologics in children with atopic dermatitis.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region